Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (4593)	2/23/2006 2:58:12 PM
From: nigel bates	Respond to of 4974

Dunno, but the BIO seems to think it's a problem - Message 21957695 - and I know that a few European biotechs have already dropped their plans to list in the US. London's AIM (Alternative Investment Market) is certainly getting a new lease of life, albeit with rather too many dodgy mining & oil exploration companies...

To: keokalani'nui who wrote (4593)	2/24/2006 3:55:14 AM
From: mopgcw	Read Replies (3) \| Respond to of 4974

Really. How hard could this possibly be for a development stage biotech? Two check signers, two accountants, and you're done. I assume you are tongue-in-cheek, but if not in my dreams...it really is a nightmare. I cant speak for a bio firm, but in ours -- ugly. I do think a part of the issue is the legislation, and the other is that acct firms have become so cautious now that it is really having an impact on the bottom line -- it is not just accounting but also operational.